Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coramitug - Novo Nordisk

Next Previous
X
Search
Drug Profile

Coramitug - Novo Nordisk

Alternative Names: NN-6019; NNC6019-0001; PRX-004

Latest Information Update: 19 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neotope Biosciences
  • Developer Novo Nordisk
  • Class Cardiovascular therapies; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Protein aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Transthyretin-related hereditary amyloidosis
  • Phase I Cardiovascular disorders

Most Recent Events

  • 16 Feb 2024 Prothena completes enrolment in its phase II trial in Transthyretin-related hereditary amyloidosis in USA, Canada, Czech Republic, France, Germany, Italy, Japan, Spain, Portugal, Netherlands, Spain (IV) (NCT05442047) (EudraCT2021-006226-49)
  • 30 Oct 2023 Phase-II clinical trials in Transthyretin-related hereditary amyloidosis in Canada, France, Japan, Italy (IV) (NCT05442047) (EudraCT2021-006226-49)
  • 28 Jul 2023 No recent reports of development identified for phase-I development in Transthyretin-related-hereditary-amyloidosis in Sweden (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top